Literature DB >> 31506753

Fatal encephalopathy after pembrolizumab treatment for advanced non-small cell lung carcinoma.

Cláudia Freitas1,2, Luísa Sampaio3,4, Gabriela Fernandes5,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31506753     DOI： 10.1007/s11060-019-03289-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  4 in total

Review 1.  Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors.

Authors:  Sophie Feng; Jermaine Coward; Elizabeth McCaffrey; John Coucher; Paul Kalokerinos; Ken O'Byrne
Journal:  J Thorac Oncol       Date:  2017-08-24       Impact factor: 15.609

2.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

3.  Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.

Authors:  Justin C Kao; Bing Liao; Svetomir N Markovic; Christopher J Klein; Elie Naddaf; Nathan P Staff; Teerin Liewluck; Julie E Hammack; Paola Sandroni; Heidi Finnes; Michelle L Mauermann
Journal:  JAMA Neurol       Date:  2017-10-01       Impact factor: 18.302

4.  Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma.

Authors:  Catherine Maurice; Raphael Schneider; Tim-Rasmus Kiehl; Prashant Bavi; Michael H A Roehrl; Warren P Mason; David Hogg
Journal:  Cancer Immunol Res       Date:  2015-09-29       Impact factor: 11.151
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.